{"id":"NCT01652716","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes","officialTitle":"A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-Controlled, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Exenatide Twice Daily in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2012-07-30","resultsPosted":"2015-09-16","lastUpdate":"2018-07-03"},"enrollment":377,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Exenatide once weekly suspension","otherNames":[]},{"type":"DRUG","name":"Exenatide twice daily","otherNames":["Byetta"]}],"arms":[{"label":"Exenatide once weekly suspension","type":"EXPERIMENTAL"},{"label":"Exenatide twice daily (BID)","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus.\n\nTo examine the long-term (52 weeks of treatment) safety and effect on glucose control of exenatide suspension administered once weekly in subjects with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","timeFrame":"Baseline to Week 28","effectByArm":[{"arm":"Experimental: Exenatide QWS Suspension","deltaMin":-1.39,"sd":0.093},{"arm":"Active Comparator: Exenatide BID","deltaMin":-1.02,"sd":0.1147}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0072"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":58,"countries":["United States"]},"refs":{"pmids":["33037036","28685973"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":229},"commonTop":["Nausea","Injection Site Nodule","Diarrhoea","Headache","Upper Respiratory Tract Infection"]}}